Reminder: BioSig to Host Conference Call and Webcast on September 15, 2020 to Discuss Unblinding of PURE EP Human Data
September 14 2020 - 10:29AM
- Peer-reviewed, blinded, randomized data recently
presented at ESC Congress 2020
- Commercial market update discussion
- Presentation to include webcast
Westport, CT, September 14, 2020 — BioSig Technologies,
Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical
technology company developing a proprietary biomedical signal
processing platform designed to improve signal fidelity and uncover
the full range of ECG and intra-cardiac signals, today announced it
will host a call and webcast to discuss the results from the first
randomized, blinded signal sample analysis in the PURE EP 2.0
Clinical Study. The data was generated during atrial fibrillation
ablation procedures conducted at St. David’s Medical Center,
Austin, Texas.
Conference Call Details:Date: Tuesday,
September 15, 2020Time: 11:00 AM Eastern Time (ET) Dial in Number
for U.S. Callers: 1-877-407-8293 Webcast link:
https://event.webcasts.com/starthere.jsp?ei=1369137&tp_key=cbdbc3a4b8
A replay will be available for two weeks starting on September
15, 2020, at approximately 3:00 PM ET. To access the replay, please
dial 877-660-6853 in the U.S. The conference ID# is 13709732.
On August 04, 2020, BioSig announced that the Company installed
its PURE EP(tm) System at Massachusetts General Hospital (MGH) as
part of an expanding clinical study. “The PURE EP(tm) System
evaluation and data collection at MGH will commence under the
leadership of investigator Moussa Mansour M.D., Director of
MGH’s Cardiac Electrophysiology Laboratory and Atrial
Fibrillation Program.”
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024